US Broker Ratings

AnaptysBio, Inc. (ANAB) Stock Analysis: A High-Risk, High-Reward Bet with a 79% Potential Upside

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company headquartered in San Diego, California, has been capturing the attention of investors with its promising pipeline of immunology therapeutics. Despite the volatile..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Insights into a Healthcare Player with a 32% Revenue Growth

Phibro Animal Health Corporation (NASDAQ: PAHC) stands at an intriguing intersection within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. With a market capitalization of approximately..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unlocking a Potential 218% Upside in the Biotech Arena

Anavex Life Sciences Corp. (AVXL) is making headlines in the biotechnology sector with a potential upside of 218.20%, as indicated by its average target price of $34.33. As a clinical-stage..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Potential 138% Upside in the Biotech Arena

Investors eyeing the biotechnology sector may find Nurix Therapeutics, Inc. (NASDAQ: NRIX) a compelling prospect, as it offers a potential upside of 138.28%. As a clinical-stage biopharmaceutical company, Nurix focuses..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: 93% Potential Upside Sparks Investor Interest

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a promising player in the biotechnology sector, is making waves with its potential upside of 92.96%. For investors searching for growth opportunities in the healthcare..

Savara Inc. (SVRA) Stock Analysis: Exploring a 222.49% Potential Upside in Biotech

Savara Inc. (SVRA), a clinical-stage biopharmaceutical company headquartered in Langhorne, Pennsylvania, is making waves in the healthcare sector, specifically within the biotechnology industry. With a market capitalization of $378.51 million,..

uniQure N.V. (QURE) Stock Analysis: Biotech Innovator with Over 150% Potential Upside

uniQure N.V. (NASDAQ: QURE), a Netherlands-based biotech company, is attracting attention in the healthcare sector with a substantial potential upside of 152.63%, as suggested by its average analyst target price...

RxSight, Inc. (RXST) Stock Analysis: Exploring a 62% Potential Upside in the Medical Devices Sector

For investors considering opportunities within the healthcare sector, particularly in the rapidly evolving field of medical devices, RxSight, Inc. (NASDAQ: RXST) presents a compelling case. This Aliso Viejo, California-based company..

SI-BONE, Inc. (SIBN) Stock Analysis: A Healthcare Innovator with 33.55% Potential Upside

SI-BONE, Inc. (NASDAQ: SIBN), a leading player in the healthcare sector, is making waves in the medical devices industry. With a focus on addressing musculoskeletal disorders of the sacropelvic anatomy,..

Akebia Therapeutics, Inc. (AKBA)

⚠️ No article content returned.

..

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis: Unpacking the 106.66% Potential Upside

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) presents an intriguing opportunity for investors with its focus on developing therapies for central nervous system (CNS) disorders. The Boston-based company is deeply engaged..

Gyre Therapeutics, Inc. (GYRE): Investor Outlook on a Biotech Stock with 146% Potential Upside

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a San Diego-based biotechnology company specializing in small-molecule anti-inflammatory and anti-fibrotic drugs, has captured investor attention with its potential for significant price appreciation. With a..

Xeris Biopharma Holdings (XERS) Stock Analysis: A Promising Biotech with 32.63% Potential Upside

Investors looking to tap into the dynamic world of biotechnology may find Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) an intriguing prospect. With its strategic focus on chronic endocrine and neurological..

Ardelyx, Inc. (ARDX) Stock Analysis: A Potential 151% Upside in the Biotech Sector

Ardelyx, Inc. (NASDAQ: ARDX) is a compelling player in the biotechnology sector, attracting significant investor attention due to its innovative approach to treating unmet medical needs. With a market cap..

Intellia Therapeutics (NTLA) Stock Analysis: Exploring a 247% Potential Upside in Biotech Innovation

Intellia Therapeutics, Inc. (NTLA) stands at the forefront of the biotechnology sector, spearheading advancements in gene editing technologies that have the potential to revolutionize treatment paradigms for genetic and autoimmune..

RingCentral, Inc. (RNG) Stock Analysis: Exploring a Potential 16.53% Upside with Strong Analyst Support

RingCentral, Inc. (NYSE: RNG), a prominent player in the technology sector, operates within the software application industry, delivering cutting-edge cloud-based communication and collaboration solutions. With a market capitalization of $2.67..

OneConnect Financial Technology (OCFT) Stock Analysis: Navigating the Challenges with a -58.32% Potential Downside

OneConnect Financial Technology Co., Ltd. (NYSE: OCFT), a China-based provider of cloud-platform-based Fintech solutions, is currently in the spotlight of investors navigating the volatile waters of the technology sector. With..

Salesforce, Inc. (CRM) Stock Analysis: Evaluating a 31% Potential Upside Amid Strong Analyst Support

Salesforce, Inc. (NYSE: CRM) continues to be a focal point in the technology sector, particularly within the software application industry. With a current market capitalization of $257.36 billion, the company..

Autodesk, Inc. (ADSK) Stock Analysis: Analysts Signal 8.85% Upside Potential

Investors with a keen eye on the technology sector may find Autodesk, Inc. (NASDAQ: ADSK) an intriguing option, as the stock currently presents a potential upside of 8.85%, according to..

Digital Turbine, Inc. (APPS) Stock Analysis: Navigating Challenges in the Mobile Growth Arena

Digital Turbine, Inc. (NASDAQ: APPS), a player in the dynamic technology sector, operates a robust mobile growth platform designed to serve advertisers, publishers, carriers, and device OEMs. Despite its innovative..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds